Rein therapeutics inc.RNTX.US Overview

US StockHealthcare

(No presentation for RNTX)

Overview AI Analysis AI Earnings Summary Financials Financial Forecast Stock Sentimental Institutions TradingView Chart

RNTX Overall Performance

RNTX AI Analysis & Strategy

RNTX Recent Performance

9.24%

Rein therapeutics inc.

0.81%

Avg of Sector

-1.14%

S&P500

RNTX PowerScanner

RNTX Key Information

RNTX Valuation Metrics

RNTX Earnings Table

RNTX Profile

Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.